S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers|
|AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors|
|Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia|
|Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration|
|Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia|
|Pharmacyclics Appoints Chief Commercial Officer|
|Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results|
|Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma|
|IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting|
|AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers (2014/11/4)|
Click above to view more mutual fund data and stats for pcyc - Pharmacyclics Inc.